Search results
Wegovy & other GLP-1 drugs to get coverage under Medicare Part D
AARP· 6 days agoThe FDA recently approved a new use for Wegovy (semaglutide), the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are ...
Florida Blue Medicare Advantage 2024 Review - NerdWallet
Nerdwallet· 3 days agoStar ratings are determined by the Centers for Medicare & Medicaid Services (CMS). Florida Blue...
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoExelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses...
What if I can't find a doctor? Physician shortage will change how Americans receive care.
USA TODAY Opinion via Yahoo News· 6 days agoFDA approval may help burst Big Pharma myths. Making it easier for patients to take their medicines...
Here Are the Fastest Ways to Save on Your Prescription Drugs
The Motley Fool· 2 days agoIf prescription drug prices are straining your personal finances, your insurance coverage might be...
GSK raises forecasts on strong vaccine, HIV drug sales
BioPharma Dive via Yahoo Finance· 6 days agoSales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals...
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
BioPharma Dive via Yahoo Finance· 6 days agoSales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first...
Pfizer stock gains 7% after earnings beat, company calls dividend 'secure'
Yahoo Finance· 5 days agoEliquis represents nearly 14% of Pfizer’s Q1 revenue, and we recognize the uncertainty tied to the...
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Zacks via Yahoo Finance· 5 days agoSales of Tyvaso DPI were driven by higher volumes and increased commercialization utilization of the...
Earnings call: GSK forecasts growth with strong Q1 performance By Investing.com
Investing.com· 3 days agoGSK upgraded its full-year guidance, expecting another year of substantial growth for shareholders,...